Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69225 | 0.97 | — | — | |
| SCHEMBL29602556 | 0.97 | — | — | |
| Water SCHEMBL11543448 | 0.95 | TAAR1 (0.52) | TAAR1IDO1MEN1KMT2ALMNA | |
| Phosphine SCHEMBL4870115 | 0.95 | TAAR1 (0.52) | TAAR1IDO1MEN1KMT2ALMNA | |
| SCHEMBL23860531 | 0.95 | TAAR1 (0.52) | TAAR1IDO1MEN1KMT2ALMNA | |
| Alcohol SCHEMBL28982441 | 0.86 | TAAR1 (0.45) | TAAR1IDO1MEN1KMT2ALMNA | |
| SCHEMBL10567340 | 0.83 | TAAR1 (0.46) | TAAR1IDO1MEN1KMT2ALMNA | |
| Pentachlorophenol SCHEMBL10767431 | 0.81 | TAAR1 (0.41) | TAAR1IDO1MEN1KMT2ALMNA | |
| SCHEMBL8108088 | 0.78 | TAAR1 (0.41) | TAAR1IDO1MEN1KMT2ALMNA | |
| SCHEMBL3157328 | 0.78 | CXCL8 (0.59) | IDO1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394993-B2 | Process for the preparation of pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2013-03-12 | — | — | US | claimed |
| US-20100274020-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-10-28 | — | — | US | claimed |
| US-8394993-B2 | Process for the preparation of pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2013-03-12 | — | — | US | disclosed |
| EP-2231575-B1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2011-06-22 | — | — | EP | disclosed |
| US-20100274020-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-10-28 | — | — | US | disclosed |
| EP-2231575-A2 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Müködö Részvénytársaság (HU) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009068923-A2 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG (HU) | 2009-06-04 | — | — | WO | disclosed |
| EP-1054865-A1 | FARNESYL TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041235-A1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| US-4753932-A | ANTIGLUCOCORTICOID ACTIVITY | ROUSSEL UCLAF (FR) | 1988-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274020-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | PF4, F2, F3 | TAAR1 3966/4885IDO1 3637/4885MEN1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.